Adrian joined BioFab as CEO in early 2020. Previously he was CEO of MIP Diagnostics developing the business from an academic spin out to viable commercial entity valued at 30x that when he joined. Having received a PhD from Southampton University, Adrian has worked in agrochemical and drug discovery in both Scientific and Business Development roles. In 2010 he joined Abcam, the leading provider of research antibodies where he was Strategic Market Development Leader, before taking on C-level commercial roles with companies developing novel affinity reagents. Adrian’s deal record includes several multi-million pound contracts with global blue chip companies, such as Eli Lilly, Moderna and BASF, as well as a £10M corporate acquisition.